美国风湿病学会/欧洲抗风湿病联盟类风湿关节炎缓解标准:2022年修订版
基于4项随机试验的2048例类风湿关节炎患者数据,验证将患者总体评估(PtGA)阈值从1 cm提高至2 cm的布尔缓解标准(Boolean2.0)及基于指数的缓解标准。Boolean2.0较Boolean1.0使更多患者达到缓解,且与SDAI/CDAI缓解标准的一致性更好,对影像学和功能结局的预测价值未受影响。ACR和EULAR认可了修订后的布尔标准及先前暂定的指数标准。
要点
- Boolean2.0较Boolean1.0使早期RA缓解比例从14.8%升至20.6%,建立期RA从4.2%升至6.0%。
- Boolean2.0与SDAI或CDAI缓解标准的一致性优于Boolean1.0,尤其在早期病程中。
- Boolean2.0、SDAI、CDAI缓解标准预测影像学无进展和HAQ≤0.5的阳性似然比相似(3.8-4.3)。
核心结论
- 采用Boolean2.0标准可使更多患者被归类为达到缓解,并提高与基于指数的缓解标准的一致性,同时不损害对影像学或功能结局的预测价值。
- 修订后的布尔定义和先前暂定认可的指数标准获得了ACR和EULAR的认可。
研究设计与样本
- 研究使用4项比较生物制剂改善病情抗风湿药与甲氨蝶呤或安慰剂的随机试验数据,共纳入2048例试验参与者,其中早期RA 1101例,建立期RA 947例。
- 研究比较了PtGA阈值2 cm(Boolean2.0,范围0-10 cm)与原始阈值1 cm(Boolean1.0),并分析了布尔标准与基于指数标准(SDAI和CDAI)缓解之间的一致性,以及各缓解定义对后期良好身体功能(HAQ评分≤0.5)和影像学无进展的预测能力。
主要发现
- 治疗开始后6个月时,使用Boolean2.0较Boolean1.0,早期RA的缓解比例从14.8%升至20.6%,建立期RA从4.2%升至6.0%。
- Boolean2.0与SDAI或CDAI缓解标准的一致性优于Boolean1.0,尤其在早期病程中。
- Boolean2.0、SDAI和CDAI缓解标准预测影像学无进展和HAQ评分≤0.5的阳性似然比相似(阳性LR 3.8-4.3)。
- 省略PtGA(BooleanX)会恶化对良好功能结局的预测。
关键数值与推荐
- 修订后的布尔缓解标准采用PtGA阈值2 cm(Boolean2.0,范围0-10 cm),原始阈值为1 cm(Boolean1.0)。
- 基于指数的缓解标准包括SDAI和CDAI。
- Boolean2.0、SDAI和CDAI缓解标准预测影像学无进展和HAQ评分≤0.5的阳性似然比为3.8-4.3。
临床怎么用
- 使用Boolean2.0标准可对更多患者判定为缓解,并提高与基于指数缓解标准的一致性,且不损害对影像学或功能结局的预测价值。
- 修订后的布尔定义和先前暂定认可的指数标准已获得ACR和EULAR认可。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean- and index-based. Based on recent studies indicating that a higher threshold for the patient global assessment (PtGA) may improve agreement between the 2 sets of criteria, our goals were to externally validate a revision of the Boolean remission criteria using a higher PtGA threshold and to validate the provisionally endorsed index-based criteria. METHODS: We used data from 4 randomized trials comparing biologic disease-modifying antirheumatic drugs to methotrexate or placebo. We tested the higher proposed PtGA threshold of 2 cm (Boolean2.0) (range 0-10 cm) compared to the original threshold of 1 cm (Boolean1.0). We analyzed agreement between the Boolean- and index-based criteria (Simplified Disease Activity Index [SDAI] and Clinical Disease Activity Index [CDAI]) for remission and examined how well each remission definition predicted later good physical function (Health Assessment Questionnaire [HAQ] score ≤0.5) and radiographic nonprogression. RESULTS: Data from 2,048 trial participants, 1,101 with early RA and 947 with established RA, were included. The proportion of patients with disease in remission at 6 months after treatment initiation increased when using Boolean2.0 compared to Boolean1.0, from 14.8% to 20.6% in early RA and 4.2% to 6.0% in established RA. Agreement between Boolean2.0 and the SDAI or CDAI remission criteria was better than for Boolean1.0, particularly in early disease. Boolean2.0, SDAI, and CDAI remission criteria had similar positive likelihood ratios (LRs) to predict radiographic nonprogression and a HAQ score of ≤0.5 (positive LR 3.8-4.3). The omission of PtGA (BooleanX) worsened the prediction of good functional outcomes. CONCLUSION: Using the Boolean 2.0 criteria classifies more patients as achieving remission and increases the agreement with index-based remission criteria without jeopardizing predictive value for radiographic or functional outcomes. This revised Boolean definition and the previously provisionally endorsed index-based criteria were endorsed by ACR and EULAR.
引用
- Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Arthritis Rheumatol. 2022. PMID: 36274193. doi:10.1002/art.42347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。